PARVB

PARVB (beta-parvin) is a focal adhesion adaptor that couples integrin engagement to Rho-family GTPase signaling and cell motility (PMID:12499396). It physically interacts with the guanine nucleotide exchange factor ARHGEF6 (alphaPIX) through both the CH and coiled-coil domains of ARHGEF6, and the two proteins co-localize at lamellipodia and ruffles in cells spreading on fibronectin, placing PARVB upstream of Rac1/Cdc42 activation (PMID:12499396). PARVB also operates as a regulator of cell survival: it associates with the kinase TAK1 and protects it from degradation by blocking the E3 ligase ITCH from binding and ubiquitinating TAK1, so that loss of PARVB promotes TAK1 degradation and sensitizes proximal tubular epithelial cells to cisplatin-induced death and inflammation (PMID:39235496). In a separate survival axis, PARVB acts downstream of FSCN2/PPAR-γ and negatively modulates the ILK–AKT pathway, with PARVB knockdown restoring ILK-AKT activity and promoting proliferation and migration (PMID:38374196). PARVB expression is transcriptionally induced under hypoxia through HIF-1α/2α binding to a hypoxia-responsive element in its promoter, and its function as a driver of cell migration, invasion, and proliferation has been demonstrated across melanoma and tongue squamous cell carcinoma models (PMID:25422907, PMID:38301409).

1. 2003 High

   Established the first direct molecular partner of PARVB, linking it physically to the integrin-to-GTPase signaling machinery rather than treating it as a generic adhesion protein.

   Evidence Yeast two-hybrid, reciprocal Co-IP, GST pull-down, domain-deletion mapping, and immunofluorescence co-localization on fibronectin

   PMID:12499396

   Open questions at the time

   • Whether PARVB directly modulates ARHGEF6 GEF activity toward Rac1/Cdc42 was not measured
   • No structural detail of the PARVB-ARHGEF6 interface
2. 2024 High

   Defined a survival role for PARVB by showing it stabilizes TAK1 protein through competitive blockade of ITCH-mediated ubiquitination, explaining how PARVB loss sensitizes cells to injury.

   Evidence Conditional Cre-LoxP knockout in proximal tubular epithelium, Co-IP of PARVB-TAK1 and ITCH-TAK1, ubiquitination assay, and PARVB/TAK1 rescue plus in vivo cisplatin model

   PMID:39235496

   Open questions at the time

   • Whether PARVB occludes the ITCH binding site directly or allosterically is unresolved
   • Generalizability beyond renal tubular cells untested
3. 2024 Medium

   Positioned PARVB within the FSCN2/PPAR-γ axis as a negative modulator of the ILK-AKT survival pathway in cochlear cells.

   Evidence Fscn2 knockout mouse, microarray, siRNA knockdown, overexpression rescue, PPAR-γ inhibition, and Western blot of ILK/p-AKT/Bcl-2/Caspase9

   PMID:38374196

   Open questions at the time

   • No direct biochemical reconstitution of a PARVB-ILK interaction
   • Mechanism by which PARVB suppresses ILK activity unclear
4. 2024 Medium

   Identified hypoxia as an upstream transcriptional driver of PARVB and tied its expression to tumor cell motility and growth.

   Evidence HIF-1α/2α knockdown, promoter hypoxia-responsive element analysis, in vitro proliferation/migration/invasion assays, and melanoma xenograft

   PMID:38301409

   Open questions at the time

   • Direct HIF binding to the PARVB promoter element not shown by ChIP
   • Downstream effectors of PARVB in melanoma not defined
5. 2024 Medium

   Confirmed PARVB as a functionally required driver of cell motility in a second cancer context.

   Evidence siRNA knockdown with migration and wound-healing assays in tongue squamous cell carcinoma cells

   PMID:25422907

   Open questions at the time

   • No molecular pathway linking PARVB to migration in this model
   • Single lab, related rather than orthogonal assays
6. 2025 Low

   Extended PARVB's pro-tumor role to additional contexts and candidate effector pathways (JAK2/STAT3 and EMT, PALB2-dependent macropinocytosis, and a SMAD3-TNFSF13 immunosuppressive axis).

   Evidence In vitro knockdown/overexpression, 3D spheroid and macropinocytosis assays, transcriptomic/scRNA-seq and multiplex IHC across glioblastoma, PALB2-mutated breast, and cervical cancer

   PMID:34568031 PMID:40730089 PMID:40744226

   Open questions at the time

   • No direct biochemical validation of PARVB-JAK2/STAT3 or PARVB-SMAD3 interactions
   • Mechanism placing PARVB downstream of PALB2 unresolved
   • Pathway links inferred largely from transcriptomic/IHC correlation

• How PARVB integrates its distinct roles—ARHGEF6/GTPase scaffolding, TAK1 stabilization, and ILK-AKT modulation—into a unified mechanism, and which domains govern each, remains unresolved.
• No structural model of PARVB defining domain-specific partner binding
• Whether the survival and migration functions are mechanistically coupled is unknown